PeptidePedia The community reference

Special:RecentChanges

Change log·6,798 revisions·page 41 of 68

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 6,798 changes are logged in total.

6,798Logged changes
575Bot edits
167Page creations
256Active editors

2 May 2025

  1. (diff | hist) 13:42 Temperature excursion 5,809 +1,019 SupplyWatchSuri (talk | contribs) expand §Quantifying an excursion [rollback]
  2. (diff | hist) 12:23 Shanghai Sigma-Audley New Material Technology 8,889 +602 Peptide_Pete (talk | contribs) expand §External links [rollback]
  3. (diff | hist) 10:11 Talk:Hubei Jianxiang Bioscience 400 +354 SupplyWatchSuri (talk | contribs) /* Dispatch address versus registered address */ new section
  4. (diff | hist) 09:57 Dulaglutide 4,161 ±0 Areapercent_Ayo (talk | contribs) de-duplicate a repeated sentence [rollback]
  5. (diff | hist) m 07:48 Chain of custody 4,085 ±0 BatchNumberBede (talk | contribs) add the note on how to request a batch record rather than a certificate [rollback]

1 May 2025

  1. (diff | hist) 20:44 Semaglutide 8,560 +481 SecretagogueSol (talk | contribs) reorder the analogues chronologically rather than alphabetically [rollback]
  2. (diff | hist) 17:09 Placebo-adjusted effect 3,893 ±0 LiraLotte (talk | contribs) add the confidence interval to the point estimate [rollback]
  3. (diff | hist) m 14:10 Injection site rotation 4,064 ±0 ColdChainCleo (talk | contribs) add the sharps-disposal cross-link [rollback]
  4. (diff | hist) 13:19 Electrospray ionisation 3,512 ±0 IsocraticIla (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  5. (diff | hist) m 04:27 Regulatory status by jurisdiction 3,662 +271 Compounding_Cate (talk | contribs) attribute the compounding statement to the pharmacy board that issued it [rollback]
  6. (diff | hist) m 01:50 Reverse-phase HPLC 5,116 +834 Areapercent_Ayo (talk | contribs) split §Principle from §Practical limitations [rollback]

30 April 2025

  1. (diff | hist) 22:12 Loss on drying 3,765 +30 DataTableDunja (talk | contribs) move a stray full stop inside the reference [rollback]
  2. (diff | hist) 21:59 Liraglutide 5,268 +18 A1c_Alder (talk | contribs) clarify that the peptide backbone is acylated rather than PEGylated [rollback]
  3. (diff | hist) 19:11 Aspiration risk under anaesthesia 3,911 +31 RetinopathyRex (talk | contribs) rm the reassurance sentence; the article should report, not reassure [rollback]
  4. (diff | hist) m 11:56 Batch number 3,731 +23 PrimarySrcPatia (talk | contribs) expand §What a batch number cannot do [rollback]
  5. (diff | hist) 11:22 Talk:ChinaPeptides 1,244 +65 Ref_Desk_Ron (talk | contribs) /* Which name should the article title use? */ reply
  6. (diff | hist) 10:40 Talk:Qingdao Sigma Chemical 1,170 +109 PuffRemoverPax (talk | contribs) /* Reporting a tally count without implying a ranking */ reply
  7. (diff | hist) 09:20 Research use only 6,689 ±0 PharmDrafts (talk | contribs) fix the anchor on an internal link [rollback]
  8. (diff | hist) 08:42 Timeline of incretin therapeutics 3,954 ±0 SurvodutideSaff (talk | contribs) the lead claimed weekly dosing for a compound dosed daily; corrected [rollback]
  9. (diff | hist) 02:51 Glossary of peptide terminology 4,611 +40 MolarMassMaeve (talk | contribs) expand §Clinical and evidence [rollback]
  10. (diff | hist) 00:02 Test report forgery 4,203 ±0 CapitalisationCaz (talk | contribs) add the chain-of-custody point to §Limitations [rollback]

29 April 2025

  1. (diff | hist) 17:50 SELECT trial 4,206 ±0 SemaglutideSasha (talk | contribs) ce per PP:MOS [rollback]
  2. (diff | hist) 10:00 CagriSema 4,167 ±0 SurrogateSunday (talk | contribs) consistent en dashes in ranges [rollback]
  3. (diff | hist) 08:52 Talk:Qingdao Sigma Chemical 959 +300 NPOV_Nadia (talk | contribs) /* Reporting a tally count without implying a ranking */ reply
  4. (diff | hist) 04:02 Body composition assessment 4,384 ±0 A1c_Alder (talk | contribs) add the seasonal variation point, sourced [rollback]
  5. (diff | hist) 03:56 Hunan Aslsen Technology 10,052 +1,054 GsCouplingGil (talk | contribs) add the research-use-only statement to the lead rather than only the footer [rollback]
  6. (diff | hist) 03:15 Custom peptide synthesis 3,777 ±0 SarcopeniaSefa (talk | contribs) move a stray full stop inside the reference [rollback]
  7. (diff | hist) m 02:07 Bacteriostatic water 4,541 +193 DiluentDiya (talk | contribs) de-orphan [rollback]
  8. (diff | hist) 00:37 Insulin syringe unit conversion 4,444 ±0 TSH_Tallulah (talk | contribs) expand §Sources of error [rollback]

28 April 2025

  1. (diff | hist) 20:46 Receptor bias 3,536 ±0 GIP_Genoveva (talk | contribs) unpipe a link that did not need piping [rollback]
  2. (diff | hist) m b 18:48 Certificate of analysis 8,096 +583 CategoryBot (talk | contribs) bot: update parent category chain [rollback]
  3. (diff | hist) m 15:09 Albumin binding half-life extension 4,872 ±0 ReceptorRhoda (talk | contribs) split §Physiology from §Pharmacological exploitation [rollback]
  4. (diff | hist) 13:11 Talk:Qingdao Sigma Chemical 748 +172 TallySheetTad (talk | contribs) /* Reporting a tally count without implying a ranking */ reply
  5. (diff | hist) 11:01 Peptide supply chain 6,954 ±0 DrTitration (talk | contribs) convert the storage conditions to a table [rollback]
  6. (diff | hist) 10:28 Karl Fischer titration 7,300 +91 GradientGus (talk | contribs) ce per PP:MOS [rollback]
  7. (diff | hist) 09:33 Talk:Qingdao Sigma Chemical 537 +233 BalanceBirdie (talk | contribs) /* Reporting a tally count without implying a ranking */ new section
  8. (diff | hist) m 08:34 Customs seizure 3,644 ±0 GreyMarketGreer (talk | contribs) rm the speculation about future scheduling [rollback]

27 April 2025

  1. (diff | hist) 23:28 Peptide aggregation 4,377 ±0 SchematicScout (talk | contribs) state the column chemistry and the gradient the figure was obtained on [rollback]
  2. (diff | hist) 12:44 Vial filling and stoppering 4,012 ±0 NPOV_Nadia (talk | contribs) state the residual-moisture target with the method it is measured by [rollback]
  3. (diff | hist) m 12:02 Peptide content 6,898 ±0 Areapercent_Ayo (talk | contribs) correct the integration description — valley-to-valley, not drop-line [rollback]
  4. (diff | hist) 06:21 Lyophilisation 20,900 +873 Chromatokid (talk | contribs) add the crimp-seal step to the fill-and-finish description [rollback]
  5. (diff | hist) 04:27 Qingdao Sigma Chemical 10,611 +321 COA_Colwyn (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]
  6. (diff | hist) 00:53 Preparative HPLC purification 4,562 +696 CoI_Corin (talk | contribs) give the closure integrity test by name [rollback]

26 April 2025

  1. (diff | hist) 20:46 Crude peptide 3,916 ±0 CrudePeptidePearl (talk | contribs) state the difference between a validated shipper and an insulated box [rollback]
  2. (diff | hist) 20:04 Trial data comparison 4,355 +332 BalanceBirdie (talk | contribs) rm the administration advice; the tool computes, it does not instruct [rollback]
  3. (diff | hist) 18:31 Wuhan Wansheng Biotechnology 10,987 +746 TrialsTabitha (talk | contribs) attribute the capability claim to the organisation's own material [rollback]
  4. (diff | hist) 16:32 Hubei Jianxiang Bioscience 2,868 ±0 SPPS_Sorrel (talk | contribs) add the reception tally with its period and count stated [rollback]
  5. (diff | hist) 15:17 Oral semaglutide 3,542 ±0 Ref_Desk_Ron (talk | contribs) move the trade-name history out of the lead and into §Regulatory history [rollback]
  6. (diff | hist) 15:08 STEP trial programme 4,391 +34 MassSpecMarv (talk | contribs) state the analysis population: intention-to-treat or per-protocol [rollback]
  7. (diff | hist) m 14:10 VendorInvestigate 4,188 ±0 ClinicCorrespondent (talk | contribs) expand §What it cannot establish [rollback]
  8. (diff | hist) m b 09:47 Bachem Holding (Suzhou) 10,353 +615 CiteBot (talk | contribs) bot: normalise citation format [rollback]
  9. (diff | hist) 05:48 Flourishglobal Peptide Biotech 5,520 +159 FormularyFrida (talk | contribs) attribute the capability claim to the organisation's own material [rollback]
  10. (diff | hist) m 01:12 Third-party testing 5,770 ±0 Chromatokid (talk | contribs) fix a broken wikilink [rollback]
  11. (diff | hist) 00:45 Retatrutide 5,894 +24 ManualOfStyleMo (talk | contribs) expand §Reported clinical findings [rollback]
  12. (diff | hist) m 00:12 Peptide stability table 4,044 +26 EscalationEira (talk | contribs) expand §Why cross-source comparison is unsafe [rollback]
  13. (diff | hist) 00:08 Prior authorisation 3,226 +132 AnalyticalAnnie (talk | contribs) expand §How it operates [rollback]

25 April 2025

  1. (diff | hist) m 23:26 Survodutide 4,510 +40 TSH_Tallulah (talk | contribs) convert the substitution list to a table so the analogues line up [rollback]
  2. (diff | hist) 15:26 Medutest 3,795 ±0 ColdChainCleo (talk | contribs) ce [rollback]
  3. (diff | hist) 12:29 Insulin secretion 5,969 +527 SerialCommaSeb (talk | contribs) British spelling per PP:MOS [rollback]
  4. (diff | hist) m 10:16 LEADER trial 3,537 ±0 DMF_Dermot (talk | contribs) the percentage quoted was placebo-adjusted; label it [rollback]
  5. (diff | hist) m 06:10 Purity claim inflation 4,595 ±0 BlankVialBo (talk | contribs) expand §What a purity figure does establish [rollback]
  6. (diff | hist) 03:28 Xi'an Mokemei Biotechnology 4,751 +1,687 DiagramDelphine (talk | contribs) add the how-to-request-a-batch-record sentence to §Ordering and availability [rollback]
  7. (diff | hist) m 03:06 Dose escalation schedule 4,073 ±0 SyringeSybille (talk | contribs) expand §Representative schedules [rollback]

24 April 2025

  1. (diff | hist) m 16:14 Methionine oxidation 3,850 +268 SchemaSorcha (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  2. (diff | hist) 10:57 Talk:ChinaPeptides 1,033 +111 DisambigDenzil (talk | contribs) /* Which name should the article title use? */ reply
  3. (diff | hist) m 09:12 SUSTAIN trial programme 4,187 ±0 StyleSheetSybil (talk | contribs) attribute the subgroup finding as exploratory [rollback]
  4. (diff | hist) m 01:32 Subcutaneous injection 4,081 +42 StubTagTeodor (talk | contribs) state that swirling rather than shaking is the handling convention, sourced [rollback]

23 April 2025

  1. (diff | hist) m 23:11 Contraindications of incretin therapy 4,296 ±0 Chromatokid (talk | contribs) add the medical-disclaimer cross-link [rollback]
  2. (diff | hist) 20:34 Intention-to-treat analysis 3,822 ±0 INN_Ingrid (talk | contribs) split the results table so the two doses are separate rows [rollback]
  3. (diff | hist) 16:24 Number needed to treat 3,631 ±0 CounterfeitCato (talk | contribs) the article attributed a finding to the wrong trial in the programme [rollback]
  4. (diff | hist) 14:45 Multi-dose vial 12,489 +1,238 SyringeSybille (talk | contribs) expand §Definition and compendial basis [rollback]
  5. (diff | hist) m 14:16 Repackaging 3,958 ±0 NPOV_Nadia (talk | contribs) add the note that lyophilised material tolerates excursions better than solution [rollback]
  6. (diff | hist) 09:40 Temperature excursion 4,790 +802 CouplingCillian (talk | contribs) add the excursion tolerance with the study it derives from [rollback]
  7. (diff | hist) 09:33 Talk:ChinaPeptides 822 +195 ScopeSeverin (talk | contribs) /* Which name should the article title use? */ reply
  8. (diff | hist) m 06:56 Lixisenatide 3,215 ±0 SemaglutideSasha (talk | contribs) fix the anchor on an internal link [rollback]
  9. (diff | hist) 05:47 Area percent purity 6,569 ±0 DiluentDiya (talk | contribs) state that ultraviolet response is not uniform across impurities [rollback]
  10. (diff | hist) m b 03:19 Sangon Biotech 7,417 +512 ArchiveBot (talk | contribs) bot: add supplier category [rollback]
  11. (diff | hist) 02:29 Cold chain 20,418 ±0 PurityClaimPia (talk | contribs) de-orphan [rollback]
  12. (diff | hist) m 02:11 Active pharmaceutical ingredient 3,553 ±0 TrialsTabitha (talk | contribs) unpipe a link that did not need piping [rollback]

22 April 2025

  1. (diff | hist) 23:33 Dipeptidyl peptidase-4 6,022 ±0 LCellLeif (talk | contribs) ce [rollback]
  2. (diff | hist) 18:19 SURMOUNT trial programme 3,589 +30 ForestPlotFinn (talk | contribs) state that the trial has reported but is not yet peer-reviewed [rollback]
  3. (diff | hist) m b 17:54 Retention time 3,306 ±0 CiteBot (talk | contribs) bot: normalise citation format [rollback]
  4. (diff | hist) 14:16 Talk:ChinaPeptides 611 +259 INN_Ingrid (talk | contribs) /* Which name should the article title use? */ reply
  5. (diff | hist) 11:41 Talk:ChinaPeptides 400 +266 MoveRequestMio (talk | contribs) /* Which name should the article title use? */ new section
  6. (diff | hist) 07:01 Nantong Guangyuan Chemical 10,281 +675 SiteReactionSuz (talk | contribs) serial comma per PP:MOS [rollback]
  7. (diff | hist) m 04:20 Enteroendocrine L cell 4,648 +29 NauseaNoor (talk | contribs) expand §GLP-1 synthesis and secretion [rollback]
  8. (diff | hist) m 02:50 Weight regain after discontinuation 4,031 ±0 FlowTrialFraser (talk | contribs) add the interaction with the mechanism that explains it [rollback]

21 April 2025

  1. (diff | hist) m 21:19 Global access disparity 3,200 +581 AppealsArno (talk | contribs) fix the anchor on an internal link [rollback]
  2. (diff | hist) m b 21:02 Hubei Jianxiang Bioscience 2,868 +701 CiteBot (talk | contribs) bot: normalise citation format [rollback]
  3. (diff | hist) m b 18:47 Analytical method validation 5,053 +611 ArchiveBot (talk | contribs) bot: flag bare reference [rollback]
  4. (diff | hist) m 17:26 Peptide synthesis 4,134 +21 BalanceBirdie (talk | contribs) expand §Why yield falls with length [rollback]
  5. (diff | hist) 13:28 GLP-1 receptor 6,418 ±0 Retention_Time_Rae (talk | contribs) clarify that the receptor is expressed outside the pancreas [rollback]
  6. (diff | hist) m 10:10 Counterfeit peptide 4,002 +26 AppendixAlva (talk | contribs) clarify that a signature on a certificate is a release, not a verification [rollback]
  7. (diff | hist) 09:31 Dual incretin agonist 4,734 ±0 CuriousCallum (talk | contribs) the lead claimed weekly dosing for a compound dosed daily; corrected [rollback]
  8. (diff | hist) 08:27 Shanghai Wibson Biotechnology 6,406 +29 PanelPlannerPam (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  9. (diff | hist) m 04:41 Amylin receptor agonist 3,909 ±0 MetricMabel (talk | contribs) expand §Clinical findings [rollback]
  10. (diff | hist) m 03:55 Solid-phase peptide synthesis 5,107 +31 ReceptorRhoda (talk | contribs) state the difference between a validated shipper and an insulated box [rollback]
  11. (diff | hist) m 03:16 Peptide harm reduction 3,468 +30 PatientPanelPru (talk | contribs) attribute the affordability estimate to the analysis it comes from [rollback]
  12. (diff | hist) 00:54 High-performance liquid chromatography 6,047 +36 OralSemaOswin (talk | contribs) fix hyphenation per PP:MOS [rollback]

20 April 2025

  1. (diff | hist) 23:38 Reconstitution calculator 6,229 +222 SPPS_Sorrel (talk | contribs) sentence case in headings per PP:MOS [rollback]